A Phase 1 PK and Dose Escalation and Expansion Study of DST-2970 in Patients With Prostate Cancer With Rising PSA on Treatment With Abiraterone Acetate

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 22 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Oct 2024 Status changed from active, no longer recruiting to discontinued. The dose escalation portion of the study is completed, however one expansion cohort was removed due to change in standard of care, and the second cohort was not enrolled based on future development considerations.
14 Dec 2022 Planned End Date changed from 28 Feb 2023 to 31 Mar 2023.
14 Dec 2022 Planned primary completion date changed from 30 Nov 2022 to 31 Mar 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com